---
title: "Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295933699.md"
description: "A new drug, TUDRIQEV™, has been granted accelerated approval by the FDA for use in combination with nivolumab. The drug is scheduled to be launched within the next 60 days. This approval opens up new treatment options for patients, particularly those with certain medical conditions."
datetime: "2026-08-14T12:01:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295933699.md)
  - [en](https://longbridge.com/en/news/295933699.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295933699.md)
generator: "portal-rs"
---

# Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

A new drug, TUDRIQEV™, has been granted accelerated approval by the FDA for use in combination with nivolumab. The drug is scheduled to be launched within the next 60 days. This approval opens up new treatment options for patients, particularly those with certain medical conditions.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [REPL: TUDRIQEV launch targets rapid adoption in key accounts, with expansion and new indications ahead](https://longbridge.com/en/news/298618645.md)
- [New FDA Drug Approvals - August 2026](https://longbridge.com/en/news/298751885.md)
- [Harmony Biosciences Chief Medical Officer Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/298506671.md)
- [Anthem (NASDAQ:ANTX) Director Robin Shane Readnour Sells 6,100 Shares of Stock](https://longbridge.com/en/news/298381637.md)
- [RCUS: Casdatifan and quemliclustat lead a robust pipeline with strong late-stage data and major market potential](https://longbridge.com/en/news/298364956.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**